MARKET

NVAX

NVAX

Novavax Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

71.36
+7.82
+12.31%
Opening 12:53 07/07 EDT
OPEN
62.94
PREV CLOSE
63.54
HIGH
73.00
LOW
62.54
VOLUME
6.35M
TURNOVER
270.43M
52 WEEK HIGH
277.80
52 WEEK LOW
34.88
MARKET CAP
5.58B
P/E (TTM)
-4.0347
1D
5D
1M
3M
1Y
5Y
Novavax, Moderna reach three month-high to offset YTD losses
COVID-19 vaccine makers Novavax (NASDAQ:NVAX) and Moderna (<a hr...
Seekingalpha · 1h ago
BRIEF-Novavax Says EMA Approves SK Bioscience As A Supplier Of Novavax Nuvaxovid Covid-19 Vaccine
BRIEF-Novavax Says EMA Approves SK Bioscience As A Supplier Of Novavax Nuvaxovid Covid-19 Vaccine
Reuters · 4h ago
Is Novavax Stock A Buy After Omicron Results Impress Two FDA Experts?
Is Novavax stock a buy after the company's omicron data impressed two FDA experts at a recent meeting? Is NVAX stock a buy right now?
Investor's Business Daily · 22h ago
Novavax (NVAX) COVID Jab Receives EU Nod for Adolescents
Novavax (NVAX) obtains EU approval for its Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17.
Zacks · 23h ago
Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
With the U.S. FDA saying that COVID-19 booster vaccines need to include <a href="https://seekingalpha.com/news/3853297-fda-requests-manufacturers-to-update-vaccines-for-latest-omicron-subvariants?utm_medium=referral&utm_source=webull.com" t...
Seekingalpha · 1d ago
COVID hospitalizations dip for first time since mid-April, but daily deaths reach 2 1/2-month high
While the daily average of new COVID-19 cases have settled back into a low-100K range that has lasted for about seven weeks, hospitalizations took their first dip since mid-April and deaths ticked up to a 2 1/2-month high.
marketwatch.com · 2d ago
Why Is Novavax (NVAX) Stock Rallying Today?
Investor Place · 2d ago
Novavax wins EU nod to use COVID-19 vaccine in adolescents
Novavax (NASDAQ:NVAX) announced on Tuesday that the European Commis...
Seekingalpha · 2d ago
More
No Data
Learn about the latest financial forecast of NVAX. Analyze the recent business situations of Novavax Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
57.14%Buy
14.29%Hold
14.29%Under-perform
0.00%Sell
Analyst Price Target
The average NVAX stock price target is 152.60 with a high estimate of 207.00 and a low estimate of 35.00.
High207.00
Average152.60
Low35.00
Current 71.35
EPS
Actual
Estimate
-7.56-3.94-0.323.30
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 450
Institutional Holdings: 38.21M
% Owned: 48.91%
Shares Outstanding: 78.13M
TypeInstitutionsShares
Increased
136
3.87M
New
65
2.32M
Decreased
99
5.37M
Sold Out
102
762.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.81%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Non-Executive Chairman/Independent Director
James Young
President/Chief Executive Officer/Director
Stanley Erck
Chief Financial Officer/Executive Vice President/Treasurer
James Kelly
Corporate Executive
Gregory Glenn
Chief Operating Officer/Executive Vice President
Rick Crowley
Chief Human Resource Officer/Executive Vice President
Jill Hoyt
Executive Vice President/Secretary
John Herrmann
Executive Vice President
Filip Dubovsky
Executive Vice President
John Trizzino
Senior Vice President/Chief Compliance Officer
Troy Morgan
Senior Vice President/Director of Sales
Frank Czworka
Senior Vice President/Director of Investor Relations
Silvia Taylor
Senior Vice President
Marco Cacciuttolo
Senior Vice President
Denny Kim
Senior Vice President
Raburn Mallory
Senior Vice President
Brian Rosen
Senior Vice President
Gale Smith
Senior Vice President
Henrietta Ukwu
Senior Vice President
Brian Webb
Independent Director
Gregg Alton
Independent Director
Richard Douglas
Independent Director
Rachel King
Independent Director
Margaret Mcglynn
Independent Director
David Mott
No Data
No Data
About NVAX
Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Webull offers kinds of Novavax, Inc. stock information, including NASDAQ:NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.